Clinical trial
Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory…
NCT00072722 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00072722 |
|---|---|
| Title | Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC) |
| Official title | Phase II Randomized Open-Label, Two-Arm Study of Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC) |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | CC-4047 |
| Enrollment | 36 |
| Start date | Sep 1, 2003 |
| Completion | Apr 1, 2005 |
| First posted | Nov 13, 2003 |
| Last update posted | Dec 19, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: